IXICO PLC
LSE:IXI
Intrinsic Value
IXICO Plc engages in the provision of technology-enabled specialty services to the global biopharmaceutical industry. [ Read More ]
The intrinsic value of one IXI stock under the Base Case scenario is 24.69 GBX. Compared to the current market price of 8.75 GBX, IXICO PLC is Undervalued by 65%.
Valuation Backtest
IXICO PLC
Run backtest to discover the historical profit from buying and selling IXI stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
IXICO PLC
Current Assets | 6.3m |
Cash & Short-Term Investments | 4m |
Receivables | 2.3m |
Non-Current Assets | 6.7m |
PP&E | 520k |
Intangibles | 6.2m |
Other Non-Current Assets | 30k |
Current Liabilities | 1.3m |
Accounts Payable | 1.1m |
Other Current Liabilities | 140k |
Non-Current Liabilities | 280k |
Long-Term Debt | 280k |
Earnings Waterfall
IXICO PLC
Revenue
|
6.7m
GBP
|
Cost of Revenue
|
-3.4m
GBP
|
Gross Profit
|
3.3m
GBP
|
Operating Expenses
|
-4.7m
GBP
|
Operating Income
|
-1.4m
GBP
|
Other Expenses
|
260k
GBP
|
Net Income
|
-1.2m
GBP
|
Free Cash Flow Analysis
IXICO PLC
IXI Profitability Score
Profitability Due Diligence
IXICO PLC's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
Score
IXICO PLC's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
IXI Solvency Score
Solvency Due Diligence
IXICO PLC's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Score
IXICO PLC's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IXI Price Targets Summary
IXICO PLC
According to Wall Street analysts, the average 1-year price target for IXI is 24.48 GBX with a low forecast of 24.24 GBX and a high forecast of 25.2 GBX.
Shareholder Return
IXI Price
IXICO PLC
Average Annual Return | 40.67% |
Standard Deviation of Annual Returns | 144.36% |
Max Drawdown | -94% |
Market Capitalization | 4.2m GBX |
Shares Outstanding | 48 351 373 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
IXICO Plc engages in the provision of technology-enabled specialty services to the global biopharmaceutical industry. The Company’s data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable trial design, site qualification, patient selection and clinical outcomes. The company provides technology-enabled services across all phases of clinical evaluation. The Company’s services include the collection, analysis, management and reporting of data generated during a clinical study and the outputs from the data analysis. The Company’s integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make better-informed decisions. Its geographical area includes Switzerland, United Kingdom, United States of America, Netherlands, Ireland and Europe.
Contact
IPO
Employees
Officers
The intrinsic value of one IXI stock under the Base Case scenario is 24.69 GBX.
Compared to the current market price of 8.75 GBX, IXICO PLC is Undervalued by 65%.